Satraplatin is a fourth-generation platinum-based anticancer drug developed by GPC Biotech, Inc. Unlike its predecessors cisplatin and carboplatin, which were administered intravenously, satraplatin was developed for oral administration. Satraplatin mediates its action through the formation of DNA adducts and inter- and intra-strand crosslinks. These adducts distort the DNA template with a deceleration of cells in S phase followed with G2 phase arrest. Satraplatin also inhibits DNA replication and transcription and induces signal transduction pathway, leading to cell cycle arrest and apoptosis. Satraplatin was investigated in phase III clinical trials against metastatic castrate-resistant prostate cancer. Despite the improvement in progression-free survival and palliation, overall survival was not improved with satraplatin therapy. The median survival was 61.3 weeks in the satraplatin group and 61.4 weeks in the prednisone and placebo group. In July 2007, GPC Biotech announced the withdrawal of the New Drug Application (NDA) for satraplatin, and the development of the drug was discontinued.